B2M and melanoma: Besides misdiagnosis of MMR-proficient tumors as MSI (5), non-functionality of tumor cells’ antigen presentation machinery, mediated by mutations of the Beta2-microglobulin (B2M) gene, has been discussed as a key mechanism of resistance towards ICB in some cancer types, such as melanoma (6, 7).